FDMT

FDMT

USD

4D Molecular Therapeutics Inc. Common Stock

$10.500-0.520 (-4.719%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$11.020

Hoch

$11.020

Tief

$10.040

Volumen

0.63M

Unternehmensfundamentaldaten

Marktkapitalisierung

578.4M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.80M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $2.235Aktuell $10.500Hoch $12.34

Ähnliche Nachrichten

GlobeNewswire

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336

Mehr anzeigen
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
Analyst Upgrades

RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target

RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics with a Outperform and maintains $26 price target.

Mehr anzeigen
RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target
GlobeNewswire

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with

Mehr anzeigen
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference